紫杉醇联合奈达铂治疗老年非小细胞肺癌的临床观察  

Clinical observation of paclitaxel plus nedaplatin in the treatment of advanced non-small cell lung cancer in elderly

作　　者：李代蓉[1] 李启英[1] 王莉[1] 黄德鸿[1] 

机构地区：[1]重庆市肿瘤研究所肿瘤内科,重庆400030

出　　处：《现代肿瘤医学》2012年第10期2060-2062,共3页Journal of Modern Oncology

摘　　要：目的:观察紫杉醇联合奈达铂治疗老年非小细胞肺癌的疗效和毒副反应。方法:52例老年Ⅲ-Ⅳ期非小细胞肺癌患者,应用紫杉醇135mg/m2,奈达铂60-80mg/m2,静脉滴注,d1,21-28d为1个周期,用药2个周期后评估疗效和毒副反应。结果:CR1例,PR16例,总有效率32.7%,首治患者的有效率为36.3%。主要毒副反应为骨髓抑制,消化道反应及肝肾功能损害轻微。结论:紫杉醇联合奈达铂治疗老年非小细胞肺癌有较好的临床疗效,毒副反应轻,耐受性好。Objective：To evaluate the results of combined chemotherapy with paclitaxel plus Nedaplat in treatment of advanced nonsmall cell lung cancer in elderly.Methods： All 52 patients with advanced non-samll cell lung cancer were treated with paclitaxel plus nedaplat.PTX 135mg/m2,2 by intravenous infusion on day 1,and NDP 60-80mg/m2,2 by intravenous infusion on day 1.The treatment was repeated every 21or 28 day,up to 2 cycles.Results： All 52 patients were evaluable for efficacy.The overall response rate（RR） was 32.7%（CR：1,PR：16）and 36.3% in first treatment.The major toxicities included myelosuppression,and other side effects were mild.Conclusion： Paclitaxel plus nedaplat were effective and well tolerable regimens in the treatment of advanced non-small cell lung cancer in elderly.

关 键 词：紫杉醇 奈达铂 老年肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]